Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 12/20 | 0.51 |
| ▸ | NR1H4 | Q96RI1 | 11/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2905066 | 0.84 | SCN9A (0.43) | EPHX2RAB9AMEN1NPC1KMT2A | |
| SCHEMBL2909521 | 0.83 | LMNA (0.55) | EPHX2NR1H4MAPTLMNAALDH1A1 | |
| SCHEMBL1841616 | 0.79 | ROCK2 (0.52) | EPHX2NR1H4MAPTSMN1; SMN2BTK | |
| SCHEMBL1840713 | 0.76 | ALDH1A1 (0.59) | EPHX2NR1H4MAPTSMN1; SMN2LMNA | |
| SCHEMBL2912322 | 0.76 | ESRRG (0.56) | MAPTRAB9ANPC1 | |
| SCHEMBL269559 | 0.76 | SMN1; SMN2 (0.49) | EPHX2NR1H4MAPTSMN1; SMN2LMNA | |
| SCHEMBL2007932 | 0.74 | EPHX2 (0.51) | EPHX2NR1H4MAPTLMNAALDH1A1 | |
| SCHEMBL1839844 | 0.73 | EPHX2 (0.45) | EPHX2NR1H4MAPTLMNARAB9A | |
| SCHEMBL1842237 | 0.73 | ROCK2 (0.52) | EPHX2NR1H4MAPTSMN1; SMN2LMNA | |
| SCHEMBL1838659 | 0.72 | RAB9A (0.45) | EPHX2NR1H4SMN1; SMN2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069302-B1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER (US) | 2010-08-25 | — | — | EP | claimed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | claimed |
| EP-2069302-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | Pfizer Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008032204-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS | PFIZER JAPAN INC. (JP) | 2008-03-20 | — | — | WO | claimed |
| US-8178558-B2 | Substituted pyridylmethyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178558-B2 | Substituted pyridylmethyl bicycliccarboxyamide compounds | PFIZER INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | PFIZER, INC. | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318497-A1 | SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS | CNR1, CNR2, HCAR3 | EPHX2 2655/4885NR1H4 665/4885MAPT 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.